AAAAAA

   
Results: 1-16 |
Results: 16
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir
Authors: Walmsley, SL Becker, MI Zhang, M Humar, A Harrigan, PR
Citation: Sl. Walmsley et al., Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir, ANTIVIR TH, 6(1), 2001, pp. 47-54
HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort
Authors: Alexander, CS Dong, W Chan, K Jahnke, N O'Shaughnessy, MV Mo, T Piaseczny, MA Montaner, JSG Harrigan, PR
Citation: Cs. Alexander et al., HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort, AIDS, 15(5), 2001, pp. 601-607
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing
Authors: Harrigan, PR Montaner, JSG Wegner, SA Verbiest, W Miller, V Wood, R Larder, BA
Citation: Pr. Harrigan et al., World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing, AIDS, 15(13), 2001, pp. 1671-1677
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy
Authors: Walmsley, SL Kelly, DV Tseng, AL Humar, A Harrigan, PR
Citation: Sl. Walmsley et al., Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy, AIDS, 15(12), 2001, pp. 1581-1584
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
Authors: Montaner, JSG Harrigan, PR Jahnke, N Raboud, J Castillo, E Hogg, RS Yip, B Harris, M Montessori, V O'Shaughnessy, MV
Citation: Jsg. Montaner et al., Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens, AIDS, 15(1), 2001, pp. 61-69
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
Authors: Cote, HCF Brumme, ZL Harrigan, PR
Citation: Hcf. Cote et al., Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir, J VIROLOGY, 75(2), 2001, pp. 589-594
Clinical utility of testing human immunodeficiency virus for drug resistance
Authors: Harrigan, PR Cote, HCF
Citation: Pr. Harrigan et Hcf. Cote, Clinical utility of testing human immunodeficiency virus for drug resistance, CLIN INF D, 30, 2000, pp. S117-S122
Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
Authors: Reiss, P Vella, S Cooper, D Lange, J Gartland, M Gerstoft, J Goebel, F Larder, B Clumeck, N Gatell, J Gazzard, B Rozenbaum, W Rae, S O'Shaughnessy, MV Robinson, P Harrigan, PR Raboud, J Alexander, CS Maguire, M Montaner, JS
Citation: P. Reiss et al., Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit, AIDS, 14(10), 2000, pp. 1383-1388
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy
Authors: Harrigan, PR Stone, C Griffin, P Najera, I Bloor, S Kemp, S Tisdale, M Larder, B
Citation: Pr. Harrigan et al., Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy, J INFEC DIS, 181(3), 2000, pp. 912-920
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
Authors: Montaner, JSG Mo, T Raboud, JM Rae, S Alexander, CS Zala, C Rouleau, D Harrigan, PR
Citation: Jsg. Montaner et al., Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine, J INFEC DIS, 181(2), 2000, pp. 729-732
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV
Authors: Raboud, JM Rae, S Vella, S Harrigan, PR Bucciardini, R Fragola, V Ricciardulli, D Montaner, JSG
Citation: Jm. Raboud et al., Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV, J ACQ IMM D, 22(3), 1999, pp. 260-266
Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2 '-deoxy-3 '-oxa-4 '-thiocytidine (dOTC)
Authors: Richard, N Quan, YD Salomon, H Hsu, M Bedard, J Harrigan, PR Rando, R Mansour, T Bowlin, TL Wainberg, MA
Citation: N. Richard et al., Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2 '-deoxy-3 '-oxa-4 '-thiocytidine (dOTC), ANTIVIR TH, 4(3), 1999, pp. 171-177
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
Authors: Harrigan, PR Whaley, M Montaner, JSG
Citation: Pr. Harrigan et al., Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy, AIDS, 13(8), 1999, pp. F59-F62
Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users
Authors: Alexander, CS Dong, W Schechter, MT O'Shaughnessy, MV Strathdee, SA Mo, T Montaner, JSG Harrigan, PR
Citation: Cs. Alexander et al., Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users, AIDS, 13(8), 1999, pp. 981-985
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
Authors: Harrigan, PR Hertogs, K Verbiest, W Pauwels, R Larder, B Kemp, S Bloor, S Yip, B Hogg, R Alexander, C Montaner, JSG
Citation: Pr. Harrigan et al., Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting, AIDS, 13(14), 1999, pp. 1863-1871
Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation
Authors: Raboud, JM Rae, S Hogg, RS Yip, B Sherlock, CH Harrigan, PR O'Shaughnessy, MV Montaner, JSG
Citation: Jm. Raboud et al., Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation, J INFEC DIS, 180(4), 1999, pp. 1347-1350
Risultati: 1-16 |